

The Life-long Care of Individuals with Lennox-Gastaut Syndrome

Strategies for Outcomes Optimization
from Childhood Through Adulthood



This program is supported by an independent
medical education grant from Jazz Pharmaceuticals.

This activity may include discussions of products or devices that are not currently labeled for use by the U.S. Food and Drug Administration (FDA).

The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.





Elaine Wirrell, MD
(Moderator)

Professor and Chair
Child and Adolescent Neurology
Mayo Clinic
Rochester, Minnesota



Tracy Dixon-Salazar, PhD
(Patient Advocate)

Executive Director
Lennox-Gastaut Syndrome (LGS)
Foundation
San Diego, California



Bethany Thomas, DNP

Epilepsy Nurse Practitioner
Hospital of the University
of Pennsylvania
Philadelphia, Pennsylvania

1 Learning Objective

Evaluate the disease burden and impact of Lennox-Gastaut syndrome (LGS) on quality of life (QoL) for both patients and caregivers



Learning Objective

Utilize diagnostic criteria and distinguishing features of both early- and late-onset LGS to achieve early and accurate diagnosis in all patients



Learning Objective

**Develop strategies
to optimize
management of
LGS across
patients' lifespans**

The Burden of LGS on Patients and Their Caregivers

Tracy Dixon-Salazar, PhD




Audience Response



Which of the following is a common non-seizure symptom seen in LGS?

- A. Sleep disorders
- B. Eyelid ptosis
- C. Reliance on parenteral nutrition
- D. Hydrophobia
- E. I don't know

Which of the following is a common non-seizure symptom seen in LGS?



Introduction: Savannah's LGS Journey (Age 1-5)

Unknown at birth



1st seizure

Age 2



Epilepsy

4 seizures at age 2
→ 6 months without seizure → back with a vengeance at age 3



Treatment-resistant epilepsy

Age 3

Other seizure types emerge

Developmental delay





Frequent epileptiform activity





100s of seizures a day

Interplay leads to DEE




Toddler brain development



LGS

Diagnosed at age 5



ETIOLOGY

EVOLUTION

BRAIN DAMAGE

Savannah's LGS Journey (Age 5-18)


LGS

Age 5-18



of Seizures: >40,000
Years to Get LGS Diagnosis: 3 years
Years to Find Etiology: 15
Neurologists: 7
Treatments Tried: 26
Hospitalizations: 15
Surgeries: 5
Rescue Med Uses/Month: 2-5
Monthly drug cost: \$1,640
Emergency med use: \$183/dose
Last stay: \$53,475

LGS + DEE + IDD
+
Intractable Epilepsy
+
Unknown Etiology



Impact

Seizures (all the time!):

- Weekly status and clusters/SUDEP
- Frequent aspiration pneumonia
- Regular emergency room visits and hospitalizations
- Brain matter atrophy

Developmental Delay/Intellectual Disability (inability to safely navigate the world):

- **Behavior:**
 - Aggression
 - Temper tantrums
 - Inattention
 - Obsessive-compulsive disorder (OCD)
- **Academic/Communications Issues:**
 - Can't read or write
 - Speech and language delayed/slurred
 - Inability to communicate needs
 - Memory issues/psychological slowing
- **Mobility and Physical Care Issues**
 - Severely off balance/low tone
 - Can't walk long distances
 - Doesn't dress/toilet/feed self

Sleep Issues:

- Excessive daytime sleepiness
- Nocturnal seizures
- Excessive nighttime waking

Constipation

Low Bone Density

Social Isolation

Weight Loss

Liver Issues


The Whole Family:

- Sibling issues
- Sleep issues
- Social isolation
- Financial challenges
- Access-to-care challenges
- Caregiver fatigue

Savannah's LGS Evolution (Age 18-29)

Our Hierarchy of Needs

Age 5-18



LGS

Age 18-31



Age 18

95% reduction in seizures on verapamil
99% reduction in clusters/status epilepticus
STARTED LEARNING AGAIN!!!

Savannah is now 31!

Lennox-Gastaut Syndrome

Developmental epileptic encephalopathy characterized by multiple types of drug-resistant seizures and cognitive and behavioral abnormalities

Accounts for 1%-2% of all childhood epilepsies


Often evolves from other infantile epilepsy syndromes, such as infantile epileptic spasms syndrome (IESS)/West syndrome

Typically presents between 18 months and 8 years of age with peak age of onset between 3 to 5 years

Persists into adulthood in nearly all cases

What Causes LGS?

- Broad range of causes!
- Likelihood of finding a cause depends on intensity of investigations
- Approximately 25%-35% are of unknown cause
- Both *syndrome* and *etiology* provide critical information to best manage the patient



Seizures in LGS

Hallmark Seizures of LGS


- Tonic (predominantly at night)*
- Atonic
- Atypical absence

Other Associated Seizure Types

- Epileptic spasms
- Non-convulsive status epilepticus
- Focal motor
- Focal impaired awareness
- Tonic-clonic
- Myoclonic

*Required for diagnosis.
Cross JH, et al. *Front Neurol.* 2017;8:505.

Non-seizure Symptoms in LGS



Evolution of Comorbidities with Age

- Cognitive impairment worsens with age in most patients
 - 95% have variable cognitive impairment at 5 years after onset
 - 80% have a decline in IQ by ≥ 15 points over time
 - By adulthood, most have moderate to severe cognitive impairment
- Behavior and sleep issues often become more significant in adolescence
 - Hyperactivity, autistic traits, aggression
- 15%-20% have deterioration in gait – many need a wheelchair for longer distances
- Increased swallowing difficulties may be seen with age, and some patients need gastrostomy tube placement

Impact on Patient QoL

Cognitive/behavioral

- Limited ability to communicate
- Frustration, aggression

Physical

- Risk of falls with seizures
- Need for a wheelchair


Social

- Limited social interactions
- Limited recreational activities


Mortality

- Increased mortality compared to other children


Impact on Caregiver/Family QoL



Impact on Caregiver/Family QoL



Impact on Caregiver/Family QoL



Discussion:

Impact of LGS on Patients and Caregivers



Catching It Early: Recognition and Diagnosis of LGS

Elaine Wirrell, MD



Patient Case: Connor



Connor is a 4-year-old male presenting with drug-resistant tonic seizures, focal seizures, and atypical absences



First seizures occurred at 10 months of age and Connor was initially diagnosed with non-syndromic focal epilepsy
Prior to first seizure development was normal




Behavior issues, including hyperactivity and self-injurious behavior
Increasing cognitive impairment with limited ability to speak
Video EEG with sleep confirms frequent tonic seizures with paroxysmal fast activity and interictal generalized slow spike-and-wave complexes

Audience Response

 **Which result of Connor's examination would be most likely to indicate LGS?**


- A. Inability to speak at a developmentally appropriate level
- B. Paroxysmal fast activity during sleep
- C. Recurring focal seizures
- D. Initial diagnosis of non-syndromic focal epilepsy
- E. I don't know

Which result of Connor's examination would be most likely to indicate LGS?



Evolution of LGS

- LGS often evolves from other infantile epileptic disorders
- Up to 20% of epilepsies beginning in infancy will evolve into LGS
- Evolution to LGS takes a median of 1.9 years



22 of 58 had a final diagnosis of LGS

LGS Diagnostic Triad

Multiple seizure types

- Tonic*, atypical absence, tonic and atonic drop attacks, non-convulsive status epilepticus

Abnormal EEG

- Interictal slow spike waves (<2.5 Hz)
- Paroxysmal fast rhythms (10-20 Hz) that are mainly during non-REM sleep

Cognitive impairment

- Developmental delay and/or intellectual slowing/regression or disability

*Required for diagnosis.

REM = rapid eye movement.

Specchio N, et al. *Epilepsia*. 2022;63(6):1398-1442.

Differential Diagnosis

Syndrome	Age of Onset	EEG	Tonic Seizure	Atonic Seizure	Intellect Impaired
LGS	1-8 years	<2.5 Hz spike wave and GPFA in sleep	Mandatory, most common in sleep	Common	Yes
EMAtS/Doose	1-5 years	Parietal theta and GPSW	+/-	++	Rarely
Dravet	<20 months Convulsive with fever	Nonspecific, often normal at onset	Rare	Rare	Normal at onset but delay seen over time
IESS/West	Usually <1 year	Hypsarrhythmia common but not universal	May evolve to tonic with time	No	Usually impaired
DEE-SWS	2-10 years	Marked sleep activation	No	Yes	26%-56%

DEE-SWS = developmental epileptic encephalopathy with spike-wave activation in sleep; EMAtS = epilepsy with myoclonic-atonic seizures; GPFA = generalized paroxysmal fast activity; GPSW = generalized polyspike wave; IESS = infantile epileptic spasm syndrome.
Adapted and updated from Bourgeois BFD, et al. *Epilepsia*. 2014;55(4):4-9.

Strategies for an Early Diagnosis

High degree of suspicion

- Awareness of the presenting features and diagnostic criteria is key
- Maintain a high degree of suspicion, particularly in children with previously diagnosed DEE or infantile epilepsy syndromes

Appropriate diagnostic workup

- Video EEG with sleep
- High-resolution neuroimaging when available
- Genetic investigations

Periodic review of diagnosis

- Heterogeneity of LGS presentation means the diagnostic features may not be present at onset and evolve over time
- Regularly review diagnosis of children presenting with DEEs to establish a diagnosis of LGS


Audience Response



Which change in Connor's presentation might you expect to see if he presented in his teenage years?


- A. Increase in daytime seizure frequency
- B. Greater predominance of tonic-clonic seizures
- C. Reduced slow spike-wave activity
- D. Absence of paroxysmal fast activity
- E. I don't know

Which change in Connor's presentation might you expect to see if he presented in his teenage years?



Evolution of Seizures in LGS: Tonic

- The characteristics of seizures in LGS change with age
- Most patients continue to have daily to weekly seizures
- Tonic seizures decrease in wakefulness but persist in sleep




*P < .05.

TS = tonic seizure.

Ferlazzo E, et al. *Epilepsy Res.* 2010;89(2-3):271-277.

Evolution of Seizures in LGS: Types

- The types of seizures seen in patients with LGS also change
- With increasing age:
 - Atonic seizures, atypical absences, and myoclonic seizures decrease
 - Focal seizures often increase



* $P < .05$.

AA = atypical absence; AS = atonic seizure; GTCS = generalized tonic-clonic seizure.
Ferlazzo E, et al. *Epilepsy Res.* 2010;89(2-3):271-277.

Challenges in Diagnosing LGS in Adults

- When diagnosis of LGS in childhood is missed, there are many challenges to diagnosing LGS in adults
 - Absence of early life and medical history
 - Difficulty obtaining records
 - Often very large volumes of records
 - Some characteristic features may be absent
 - Investigations are often incomplete
- Early diagnosis is best

Discussion:

Importance of an Early and Accurate Diagnosis



Providing Life-Long Care for Patients with LGS

Bethany Thomas, DNP




Audience Response




What is a key treatment goal in LGS?

- A. Achieve seizure freedom
- B. Regain patient motor skills
- C. Prevent behavioral issues
- D. Reduce seizure frequency and severity
- E. I don't know

What is a key treatment goal in LGS?



Importance of Nurses in the Multidisciplinary LGS Management Team



PCP = primary care practitioner.

Treatment Goals in LGS

Seizure control


- Target most problematic seizures
- Reduce seizure frequency and severity
- **Seizure freedom is not an achievable goal**
- If significant *epileptic encephalopathy* component, more urgent and aggressive measures should be considered

Manage comorbidities and improve QoL

- **Minimize adverse effects** of anti-seizure medications
- Use rational polypharmacy
- Manage the **non-seizure symptoms!**

Efficacy of ASMs for LGS: Systematic Review and Network Meta-Analysis

- Total of eight RCTs; 1,171 patients included
- Six of the FDA-approved ASMs were evaluated (felbamate and fenfluramine were not included)
- Outcome measure: 50% reduction in drop seizure rate



ASMs = anti-seizure medications; CI = confidence interval;
RCTs = randomized controlled trials.

Zhang L, et al. *Dev Med Child Neurol.* 2022;64(3):305-313.

Safety and Tolerability of ASMs for LGS*


Study	Treatment	Any AE, Active/Placebo	Dropouts for Any Reason, Active/Placebo	Dropouts Due to AE, Active/Placebo	Serious AEs, Active/Placebo	Most Common AEs
Ohtsuka et al	Rufinamide	27/21	4/1	4/1	1/1	Somnolence, pyrexia, decreased appetite, vomiting, status epilepticus
Glauser et al	Rufinamide	60/52	10/5	9/1	2/2	Somnolence, vomiting, pyrexia, diarrhea
Thiele et al	Pharmaceutical CBD	74/79	14/1	8/1	20/4	Diarrhea, somnolence, pyrexia, decreased appetite, vomiting
Devinsky et al	Pharmaceutical CBD	133/55	11/2	7/1	26/7	Somnolence, decreased appetite, diarrhea, URTI, vomiting, pyrexia, nasopharyngitis, status epilepticus
Sachdeo et al	Topiramate	NA	1/0	NA	11/5	Somnolence, anorexia, nervousness, behavioral problems, fatigue, dizziness, weight loss
Ng et al	Clobazam	142/40	42/18	29/12	14/2	Somnolence, pyrexia, lethargy, drooling, constipation
Motte et al	Lamotrigine	NA	3/7	3/7	3/0	Pharyngitis, fever, infection
Felbamate Study Group	Felbamate	NA	1/1	NA	8/3	URT, anorexia, vomiting, somnolence, injury, fever, insomnia, nervousness, headache, fatigue, purpura, abnormal gait, ataxia
Knupp et al	Fenfluramine	78 (0.2 mg/kg) 90 (0.7 mg/kg) / 75	--	--	4 (0.2 mg/kg) 11 (0.7 mg/kg) / 5	Decreased appetite, somnolence, fatigue

*All agents on this slide are FDA-approved for the treatment of LGS.

AE = adverse effect; CBD = cannabidiol; URTI = upper respiratory tract infection.

Zhang L, et al. *Dev Med Child Neurol.* 2022;64(3):305-313. Knupp KG, et al. *JAMA Neurol.* 2022;79(6):554-564.

Multimodal Approach to Therapy



All agents and procedures on this slide are FDA-approved for use in patients with LGS.

EMA = European Medicines Agency; MRI = magnetic resonance imaging.

Auvin S, et al. *Epilepsia Open*. 2024;10(1):85-106.

Seizure Action Plan

- Should be provided to all patients/caregivers with LGS
- Provides information on what to do in emergency situations
- Reduces time to action during seizures is reduced

What the seizures normally look like (Check all that apply)

Head May Drop Loss of Muscle Control Clonus Through the Entire Brain Blank Stare Blank Stare With Eyelid Drooping Jerky Movements Focal Impaired Awareness Seizure (also called complex partial)

☐ Atonic seizure (also called drop) ☐ Absence seizure (also called petit mal) ☐ Tonic seizure ☐ Clonic seizure ☐ Focal impaired awareness seizure (also called complex partial)

Describe: _____

NOTES: _____

Care

Standard Care Needed

If this happens, _____ provide standard care

Time the seizure Keep person safe Don't restrict Stay with person Keep a record

NOTES: _____

Provide Rescue Treatment

If this happens, _____ provide standard care (above) and rescue treatment

☐ Rectum ☐ Nose ☐ Mouth ☐ Other: _____

Specific instructions: _____

Call for Emergency Help

If any of these happen, _____

☐ Seizure longer than _____ minutes ☐ Unusual seizure ☐ Injury/Blue lips ☐ Other: _____

Call help now

Call Healthcare Provider if: _____

Call for Emergency Help if: _____

NOTES: _____

Transition From Pediatric to Adult Care

- Transition from pediatric to adult care can be difficult for both the patient and the caregiver
- Failure to plan for transition may limit access to specialty care and newer treatments and result in poor management of comorbid conditions
- Many new challenges exist when patients with LGS reach adulthood, including issues of guardianship, medical insurance, and long-term care
- Proper preparation beginning early in care can smooth the process and make successful transition more likely

Timeline of Transition Planning

No later than age 13

Initiating discussions and setting expectations



During teenage years

Review of testing and completion of missing tests



Discussions with social worker about guardianship, social security



Prior to age 18

Creation of succinct transition document by pediatric provider




Identification of adult providers for LGS and any comorbidities



Discussions and planning around adult living arrangements, insurance coverage

Resource for Transition: C.A.R.E. Binder


- The C.A.R.E. Guide is a resource designed to help families in planning long-term care for LGS
- Includes:
 - Essential factors to consider during the transition process
 - Necessary preparations for adult care
 - Available support services and resources



<https://www.lgsfoundation.org/adult-care-binder/>


Shared Decision-Making in LGS

- Shared decision-making in LGS is done predominantly with the caregiver
- Follow SHARE model:
 - **S**eek caregiver's participation
 - **H**elp caregiver explore and compare treatment options
 - **A**ssess caregiver's values and preferences
 - **R**each a decision with the caregiver
 - **E**valuate the caregiver's decision



Education and Resources for Patients and Caregivers

- Rare Epilepsy Network Resources
<https://www.rareepilepsynetwork.org/resources>
- Lennox-Gastaut Foundation Financial Resource Toolkit
<https://www.lgsfoundation.org/financial-resource-toolkit/>
- DEE-P Connections Toolkits for Parents and Siblings
<https://deepconnections.net/request-form-for-parent-or-sibling-kits/>



Discussion:

What can nurses do to facilitate the care transition process?



SMART Goals

Specific, Measurable, Attainable, Relevant, Timely

- Monitor patients and caregivers for quality-of-life challenges, and address these challenges with resources and support when possible
- Evaluate children with a history of infantile epilepsies for LGS diagnostic criteria
- Provide all patients and caregivers with a detailed seizure action plan
- Prepare patients and caregivers for the transition from pediatric to adult care by initiating discussions early and following key milestones for successful transition



Visit the Neuropsychiatry Education Hub

Free resources and education to educate
health care professionals and patients

[https://www.cmeoutfitters.com/practice/
neuropsychiatric-hub/](https://www.cmeoutfitters.com/practice/neuropsychiatric-hub/)



The Life-long Care of Individuals with Lennox-Gastaut Syndrome

Strategies for Outcomes Optimization
from Childhood Through Adulthood



This program is supported by an independent
medical education grant from Jazz Pharmaceuticals.